Epigenomics Pays Affymetrix $2M in Stock As Part of Dx Deal | GenomeWeb

NEW YORK, July 21 (GenomeWeb News) - Epigenomics yesterday paid Affymetrix 1.6 million ($2 million) worth of stock as part of the upfront payments the firms agreed to under their diagnostic alliance announced in June, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.